Ajay Sasidharan

@_joesia @cristian_udo @dr_ajays @DineshMakuny @ArchyaDasgupta We also have a phase 3 in the ALLIANCE studying this in the us, and a cog trial for pediatrics with a similar design

Hypofractionation in Glioblastoma - Time to look beyond Stupp Protocol in younger and fit patients? Promising phase 2 trials from AIIMS. @_joesia @DineshMakuny @ArchyaDasgupta

@_joesia @PeterMacRadOnc Which patients are selected for preop SRS?

- 15 pts - Median SRS-to-surgery: 8 days - No earlier surgery for growth / oedema - No Grade >2 AEs - No issues with histopath diagnosis - Interestingly, the only BrM failure at 13.8m f/u had a 0-day SRS-to-surgery interval - Lab analyses to follow! @PeterMacRadOnc

🧠💥 Pre-op SRS for brain mets is gaining traction. But must we resect 1–3 days after? 🤔 We ran a small feasibility trial. Biological rationale: keeping the irradiated tumor in situ longer may allow immune responses within the tumor to develop🕒 link.springer.com/article/10.100…

@bhash Felt bad not just for myself, but for others waiting there realising they are not getting the service they were promised.

@bhash Ola scooter brokedown. Took to service centre alloted through customer service and app, after paying pickup-auto to take my scooter. Reaching there found out that they are not taking in any service and about to close permanently (Ola centre in North Paravur, Kochi). Bad service!

And the speed at the Gigafactory now is hyper fast! Extremely proud of the team!

FAST forward Boost Trial Trial Groups (Randomized 1:1:1) Control: 48 Gy in 15 # (3 weeks). Test 1: 31 Gy in 5 fractions (1 week). Test 2: 30 Gy in 5 fractions (1 week). Aim= Is 1-week SIB radiotherapy non-inferior to 3-week SIB in terms of 5-year local relapse

Sharing our publication on Adjuvant Chemoradiation in Endometrial Cancer. thieme-connect.com/products/ejour… - 40-50% of p53 mutated patients recurred within 5 years. - Ongoing RAINBOW RED trial is testing maintenance Olaparib in p53 mutated.

𝑵𝒖𝒂𝒏𝒄𝒆𝒔 𝒐𝒇 𝑷𝒓𝒐𝒕𝒐𝒏 𝑩𝒆𝒂𝒎 𝑻𝒉𝒆𝒓𝒂𝒑𝒚: 𝑭𝒓𝒐𝒎 𝑪𝒐𝒎𝒎𝒊𝒔𝒔𝒊𝒐𝒏𝒊𝒏𝒈 𝒕𝒐 𝑪𝒍𝒊𝒏𝒊𝒄𝒔 XXII @TataMemorial Annual Radiotherapy Practicum & 1st TMC - IBA Proton Therapy Practicum 🗓 12-13 September 2025 📍@ACTREC_TMC 🔗 Register tinyurl.com/46pmefum

Prospective Largest Study for SIB N=74 (FAST); N=280 (FAST-F) SIB Dose=33 Gy(FAST);32 Gy (Fast-F) Electrons÷207; Photons (147) SIB showed worsening Cosmesis over time

Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previous studies with goal to continue same systemic treatment #bcsm

🚨 POLCA-GB RCT 🇮🇳 sets new SOC for GB cancer, NACRT improves OS over NACT! #ASCO25 Huge congratulations @ReenaEngineer Ma'am!!! Inspiring us to explore new indications, not giving up despite all challenges 💪🏼💪🏼🏆🏆

🚨Update Randomized Trial: Significantly Better KPS & Cognitive Function with SRS compared to HA-WBRT for 5-20 brain mets 🚨🚨🚨

📢 #ASCO25: In pts w/ 5–20 brain mets, SRS/SRT led to fewer symptoms & less functional interference vs HA-WBRT, w/ similar OS (~8.4 mo). 🔬 Phase 3 RCT (n=196) 💡 SRS/SRT = new SoC for brain mets >4? meetings.asco.org/abstracts-pres… #RadOnc #NeuroOnc #SRS #WBRT #BrainMets

Dr @ReenaEngineer from @RadOncTMC presents results from Ph3 randomised POLCA-GB trial for LA Gall Bladder Ca #ASCO25 Addition of NACRT to NACT shows ✅Better response to Neoadjuvant Rx ✅Higher R0 resection rates ✅Higher EFS (4.9 Vs 10.6 mos) ✅Higher OS (10.1 Vs 21.8 mos)

Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy

Dose metrics linked to bowel toxicity for rectal RT in RAPIDO: Amazing work by Max Tanaka from NKI Medium-to-high dose volumes for bowel bag (RTOG or Embrace) best predictors for both acute & late toxicity - V30Gy for LCRT, V20Gy for short course #ESTRO25 #radonc #medphys

Bounce (defined as an increase > 0.2 ng/mL) following ultra hypofrac #radiotherapy, is frequent (36%) & associated with improved prognosis. Data from HYPO RT PC at #ESTRO25 Possible bias (bounces by definition have a decrease in PSA after the rise) role of 3y landmark analysis

1/ #ESTRO2025 FAST FORWARD 10 year breast cancer results are out 40 Gy/15 fx vs 27/5 fx vs 26/5 Most women were >50y and T1N0 low risk The recurrence rate at 10y for the 26 Gy arm: 2.0% This is an INSANELY low number for risk of (any) cancer coming back To put in context:

Salvage post-RP SABR #POPART results presented by @Fefe_Ferrario @StAr_MCM74 #ESTRO25 ✅Post-op SABR is safe ✅Post-op SABR preserves QoL ✅Further FU needed to confirm clinical outcomes 📰Similar results published by @RadioterapiaHM link.springer.com/article/10.100… #radonc

PORTEC 4a results . High risk benefits from EBRT ( only 25% had LND) and low risk has small but non inferior difference in vaginal recurrence with VBT @KamravaMD @AndrewKellerMD